Personal CFO Solutions LLC Sells 105 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Personal CFO Solutions LLC cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,007 shares of the medical equipment provider’s stock after selling 105 shares during the period. Personal CFO Solutions LLC’s holdings in Intuitive Surgical were worth $344,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich lifted its position in shares of Intuitive Surgical by 99,583.4% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 643,694,311 shares of the medical equipment provider’s stock worth $220,104,833,000 after buying an additional 643,048,572 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Intuitive Surgical by 1.7% in the first quarter. BlackRock Inc. now owns 28,918,406 shares of the medical equipment provider’s stock worth $7,387,785,000 after acquiring an additional 470,624 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Intuitive Surgical by 1.0% in the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock valued at $1,642,287,000 after purchasing an additional 61,659 shares in the last quarter. Morgan Stanley grew its holdings in shares of Intuitive Surgical by 29.9% during the 4th quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock valued at $1,556,706,000 after purchasing an additional 1,351,002 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Intuitive Surgical by 1.3% during the 2nd quarter. Fisher Asset Management LLC now owns 4,444,151 shares of the medical equipment provider’s stock worth $1,519,633,000 after purchasing an additional 55,720 shares in the last quarter. Institutional investors and hedge funds own 82.91% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $305.28 on Monday. The stock has a market capitalization of $107.48 billion, a P/E ratio of 71.83, a P/E/G ratio of 4.85 and a beta of 1.31. The business has a 50 day simple moving average of $284.26 and a 200 day simple moving average of $305.11. Intuitive Surgical, Inc. has a one year low of $222.65 and a one year high of $358.07.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 19th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.40 by $0.06. Intuitive Surgical had a net margin of 22.14% and a return on equity of 12.91%. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.77 billion. During the same quarter last year, the firm posted $0.90 EPS. The company’s quarterly revenue was up 12.0% on a year-over-year basis. Equities analysts expect that Intuitive Surgical, Inc. will post 4.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 1,110 shares of the company’s stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $273.49, for a total transaction of $303,573.90. Following the transaction, the executive vice president now owns 7,259 shares in the company, valued at $1,985,263.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Robert Desantis sold 1,110 shares of the business’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $273.49, for a total value of $303,573.90. Following the completion of the sale, the executive vice president now directly owns 7,259 shares of the company’s stock, valued at approximately $1,985,263.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy L. Ladd sold 500 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $305.68, for a total value of $152,840.00. Following the transaction, the director now directly owns 702 shares in the company, valued at $214,587.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,208 shares of company stock worth $15,275,529. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $315.00 to $350.00 and gave the company a “buy” rating in a research report on Friday. SVB Leerink initiated coverage on Intuitive Surgical in a research report on Monday, October 16th. They set an “outperform” rating and a $342.00 price objective on the stock. Barclays increased their target price on Intuitive Surgical from $314.00 to $385.00 and gave the company an “overweight” rating in a research report on Monday, July 24th. Piper Sandler reduced their price target on Intuitive Surgical from $385.00 to $325.00 and set an “overweight” rating on the stock in a report on Friday, October 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $355.00 price objective on shares of Intuitive Surgical in a report on Friday, October 20th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $342.71.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.